DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dado Ruvic - 2 Jacqueline Miller - 2 Moderna - 2 BioNTech - 2 Patrick Wingrove - 2 Bill Berkrot - 2 ” - 1 Helen O'Neill - 1
Top related locs:
Britain U.S Switzerland South Africa Israel Denmark New York Europe
Top related orgs:
U.S . Food - 3 Drug Administration - 3 REUTERS - 2 World Health Organization - 2 WHO - 2 U.S . Centers for Disease Control - 2 Prevention - 2 ” Moderna - 2

Search resuls for: "Britain's Medicines"


3 mentions found


☆ UK Becomes 1st Country to Approve Gene Therapy Treatment for Sickle Cell, Thalassemia
  + stars: | 2023-11-16 | by ( Associated Press | Nov. | At A.M. | ) www.usnews.com   time to read: +4 min
LONDON (AP) — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. The agency approved the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over. Casgevy is currently being reviewed by the U.S. Food and Drug Administration; the agency is expected to make a decision early next month, before considering another sickle cell gene therapy. Millions of people around the world, including about 100,000 in the U.S., have sickle cell disease. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria.
Persons: ”, Helen O'Neill Organizations: Medicines and Healthcare Regulatory Agency, Vertex Pharmaceuticals, CRISPR Therapeutics, Helen O'Neill of University College London, Medicines, U.S . Food, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Europe, CRISPR, South Asian, Britain, U.S, Africa, India, Eastern
☆ Moderna says updated COVID vaccine is effective against newer variant
  + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +2 min
[1/2] A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsSept 6 (Reuters) - Moderna (MRNA.O) on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the dominant variant through most of 2023 and the target of the updated shots. Moderna said it had shared the new finding on its vaccine with regulators and submitted it for peer review publication. European regulators have since backed the Pfizer/BioNTech shot, with Britain's Medicines and Healthcare products Regulatory Agency approving the vaccine on Tuesday, but have yet to make any announcements on Moderna’s updated vaccine.
Persons: Dado Ruvic, Jacqueline Miller, Moderna, COVID, BioNTech, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, CDC, Omicron, U.S . Food, Drug Administration, Pfizer, Moderna, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: The Massachusetts, Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York
☆ Moderna, Pfizer say updated COVID shots generate strong response vs newer variant
  + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com   time to read: +3 min
Moderna said its shot generated an 8.7-fold increase in neutralizing antibodies against BA.2.86 compared with an untreated natural antibody response in clinical trials in humans. Pfizer said its updated vaccine with partner BioNTech (22UAy.DE) elicited a strong antibody response against BA.2.86 in a preclinical study in mice. Moderna, Pfizer/BioNTech and relative newcomer to the COVID vaccine market Novavax (NVAX.O) have created versions of their shots aimed at the XBB.1.5 subvariant, the dominant variant through most of 2023. Moderna shares were down 1.6% and Pfizer shares were off nearly 3% in afternoon trading. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the updated shots.
Persons: Moderna, Jacqueline Miller, BioNTech, Cowen, Tyler Van Buren, Dado Ruvic, Patrick Wingrove, Michael Erman, Bill Berkrot Organizations: Pfizer, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, Moderna, REUTERS, CDC, Omicron, U.S . Food, Drug Administration, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York, New Jersey
0 next >>
Total: 3